Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to $20.3 million.

  • BioCorRx's Total Liabilities rose 6049.74% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year increase of 6049.74%. This contributed to the annual value of $12.7 million for FY2024, which is 2320.54% up from last year.
  • Per BioCorRx's latest filing, its Total Liabilities stood at $20.3 million for Q3 2025, which was up 6049.74% from $19.7 million recorded in Q2 2025.
  • BioCorRx's Total Liabilities' 5-year high stood at $20.3 million during Q3 2025, with a 5-year trough of $6.1 million in Q2 2021.
  • Moreover, its 5-year median value for Total Liabilities was $9.5 million (2023), whereas its average is $10.9 million.
  • As far as peak fluctuations go, BioCorRx's Total Liabilities tumbled by 238.44% in 2021, and later skyrocketed by 6939.52% in 2025.
  • Over the past 5 years, BioCorRx's Total Liabilities (Quarter) stood at $7.8 million in 2021, then grew by 15.25% to $9.0 million in 2022, then rose by 15.31% to $10.3 million in 2023, then grew by 23.21% to $12.7 million in 2024, then surged by 59.31% to $20.3 million in 2025.
  • Its Total Liabilities was $20.3 million in Q3 2025, compared to $19.7 million in Q2 2025 and $18.6 million in Q1 2025.